flufenamic acid has been researched along with Prostatic Neoplasms in 5 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Castrate resistant prostate cancer (CRPC) is associated with increased androgen receptor (AR) signaling often brought about by elevated intratumoral androgen biosynthesis and AR amplification." | 1.38 | Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. ( Adeniji, AO; Chen, M; Christianson, DW; Penning, TM; Twenter, BM; Winkler, JD, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Purushottamachar, P | 1 |
| Khandelwal, A | 1 |
| Chopra, P | 1 |
| Maheshwari, N | 1 |
| Gediya, LK | 1 |
| Vasaitis, TS | 1 |
| Bruno, RD | 1 |
| Clement, OO | 1 |
| Njar, VC | 1 |
| Féau, C | 1 |
| Arnold, LA | 1 |
| Kosinski, A | 1 |
| Zhu, F | 1 |
| Connelly, M | 1 |
| Guy, RK | 1 |
| Adeniji, AO | 2 |
| Twenter, BM | 2 |
| Byrns, MC | 1 |
| Jin, Y | 1 |
| Chen, M | 2 |
| Winkler, JD | 2 |
| Penning, TM | 2 |
| Christianson, DW | 1 |
| Zhu, W | 1 |
| Smith, A | 1 |
| Young, CY | 1 |
5 other studies available for flufenamic acid and Prostatic Neoplasms
| Article | Year |
|---|---|
First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents; Blotting, Western; Catal | 2007 |
Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cell Line, Tu | 2009 |
Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
Topics: 20-Hydroxysteroid Dehydrogenases; 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Memb | 2012 |
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer.
Topics: Aldehyde Reductase; Androgen Antagonists; Crystallography, X-Ray; Humans; Male; Models, Molecular; O | 2012 |
A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Flufenamic Acid; Gene Expression; Homeodomai | 1999 |